'Best ever' Alzheimer's drug 'set to be blocked for NHS use' due to cost pressures

23 October 2024, 06:06

Donanemab is set to be blocked for NHS use
Donanemab is set to be blocked for NHS use. Picture: Alamy

By Kit Heren

An Alzheimer's drug deemed the "best ever" is set to be blocked for NHS use due to its high cost.

Listen to this article

Loading audio...

Donanemab, manufactured by pharmaceutical giant Eli Lilly, is a targeted antibody drug which slows down the early stages of Alzheimer's.

It is being considered by the medicines regulator and the NHS spending watchdog, with a decision due on Wednesday.

But although regulators are expected to declare donanemab safe to use, the National Institute for Health and Care Excellence (NICE) will say that it is too expensive for NHS patients, the Telegraph reported.

Scientists have said that donanemab could give Alzheimer's patients another two years of living at home, with the drug slowing the progress of the disease by 35%, with some advocates branding it the "best ever" medicine for the disease.

Read more: 'Game-changing' Alzheimer's drug Lecanemab gets the green light - but it won't be available on the NHS

Read more: Thousands to be offered blood tests for Alzheimer’s in landmark UK trial

Ben Kentish reacts as 'wonder' Alzheimer's drug is not made available under the NHS

The drug, and another new drug for Alzheimer's called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating the symptoms.

But NICE also blocked lecanemab earlier this year, despite the regulators saying that the drug was efficient at slowing Alzheimer's, making it the first drug of its kind to be licensed for use in Great Britain.

The NHS spending watchdog said the benefits of lecanemab were "just too small to justify the significant cost to the NHS".

One charity said that it is "deeply disappointing" that patients with early stage Alzheimer's will not have access to the drug on the health service "and it will only be available to those who can pay privately".

Professor Sir John Hardy says the Alzheimer's new drug is the 'real deal'

One prominent dementia researcher said that NICE was "on the wrong side of the argument".

Professor Sir John Hardy, from the UK Dementia Research Institute at UCL, told the Telegraph: “These drugs can give people an extra two years at home, rather than in a nursing home. That is time enjoying their lives, having holidays, this is important stuff. These are finely balanced arguments, but I do think they’ve come down on the wrong side of it.

“I also think that the benefit of approval would be that it would kick NHS dementia care into shape — which really needs to happen. These drugs will come down the line at some point, and I don’t think the NHS is ready for them.”

Both donanemab and lecanemab bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease.

By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline.

Evidence suggests that people get the most benefit if they are given the treatment earlier in the disease.

Distressed caller says caring for her mother with dementia is so hard she no longer wants to live

Clinical trials testing the safety and efficacy of donanemab, also known as Kisunla, found that it could slow the rate at which memory and thinking get worse by more than 20%.

Results also suggest the drug leads to a 40% reduction in the decline of everyday activities such as driving, enjoying hobbies and managing money.

The drug, which is given to patients via an intravenous drip once every four weeks, does carry a risk of side effects - some of them serious, including brain swelling and micro brain bleeds.

Some researchers have argued that the benefits of donanemab and lecanemab may not be so great as to outweigh the possible side-effects.

Sebastian Walsh of Cambridge Public Health said: "If approved, the drugs are likely to be relevant only for a relatively small cohort of Alzheimer’s patients, so potential recipients will need a range of assessments before being given access to the drugs.

“Plus, effect sizes seen in the trials are very small and the drugs will need to be administered as early in the disease process as possible, when symptoms are mild — and people in these phases can be hard to identify."

More Latest News

See more More Latest News

Piran Ditta Khan has died in jail

Gang boss behind PC Sharon Beshenivsky's murderer dies behind bars months after being locked up

Donald Trump said Zelenskyy and Putin need to 'work together'

Donald Trump says Putin and Zelenskyy 'need to work together' as he denies he's planning 'trip to Moscow'

Salman Rushdie

Man found guilty of attempted murder over Salman Rushdie attack

Diddy's lawyer has quit the sex trafficking case, a New York court heard today

‘I cannot continue’: Sean 'Diddy' Combs' lawyer quits sex trafficking case

Police officers work at the scene where a person was stabbed near the memorial of the murdered jews of Europe in Berlin

Man seriously injured in stabbing at Berlin Holocaust Memorial as police hunt suspect

Kara Alexander, 47, of Dagenham, east London, murdered Elijah Thomas, two, and Marley Thomas, five

Drug addict mother guilty of murdering her two sons then leaving bodies in bunk bed for their dad to find

The hand was found at Our Lady Immaculate school in Darndale

Mystery of ‘severed hand’ found near school in Dublin

The US has held 'positive' talks with Zelenskyy

Ukraine has 'no cards left to play' Trump claims as he slams Starmer for 'doing nothing' to end Russia's war

Pope Francis's doctors say he is 'not out of danger'

Pope Francis ‘not out of danger,’ says doctors who have prescribed ‘absolute rest’

The three brothers have been jailed for dozens of child sex offences

Three brothers jailed for sexually abusing and grooming dozens of young girls in Leeds

iPhone security update.

Urgent warning for iPhone users as Apple to remove highest level of data protection amid government security row

Steve Bannon has been accused of giving a 'Nazi' salute

Donald Trump’s former chief strategist Steve Bannon accused of doing 'Nazi salute' during speech

The US has held 'positive' talks with Zelenskyy

Talks with 'courageous' Zelenskyy were 'extensive and positive', US envoy says just days after Trump dictator comments

Actor Daniel Craig during ' Skyfall ' movie premiere in Berlin on 30th October 2012

Daniel Craig breaks silence after James Bond producers hand franchise to Amazon

Chancellor Rachel Reeves Delivers Speech On Economic Growth

Reeves breaks her fiscal rules and borrows £11.6 billion more than this time last year

Andrew Gwynne, who has said he regrets making 'badly misjudged' comments in a WhatsApp group

Labour MP sacked over vile WhatsApp messages under investigation by Parliamentary watchdog